RecruitingPhase 4NCT06474364

HIV Prevention and Care Interventions for Youth in Uganda

Using Implementation Science to Understand and Design Stakeholder Informed Innovative Interventions to Improve Youth HIV Prevention and Care Continuums in Rural and Urban Uganda.

Sponsor

MU-JHU CARE

Enrollment

600 participants

Start Date

Aug 5, 2024

Study Type

INTERVENTIONAL

Conditions

HIV

Summary

Several studies show that Adolescents and Young Adults (AYA) have poor outcomes along the entire Human Immunodeficiency Virus (HIV) prevention and care cascades compared to adults. The investigators propose to evaluate novel evidence-based HIV prevention and care interventions (including Cabotegravir LongActing (CABLA) to determine implementation outcomes among AYA who are at particularly high risk for HIV acquisition and poor viral suppression in five geographically distinct research performance sites in Uganda. The results will provide important evidence to inform Uganda and other regional countries' policy on integrated HIV prevention, care and treatment for AYA at high risk for HIV and Sexually Transmitted Infections (STIs) in order to reach the UNAIDS 95-95-95 targets and HIV epidemic control.

Eligibility

Min Age: 15 YearsMax Age: 24 Years

Plain Language Summary

Simplified for easier understanding

This study is testing better ways to prevent and manage HIV in young people (ages 15–24) in Uganda. It focuses on two groups: young people at high risk of getting HIV (offering a long-acting injectable HIV prevention drug called CAB-LA), and young people already living with HIV who may be struggling to stay in treatment. **You may be eligible if...** - You are between 15 and 24 years old - You are at high risk of getting HIV and are willing to use a prevention drug, OR - You are already living with HIV and are receiving care at a participating health facility - You are willing to provide written consent and plan to stay in the area for the study duration **You may NOT be eligible if...** - You have a positive HIV test result (if applying for HIV prevention arm) - You are already on HIV prevention medication - You have had possible HIV exposure in the past 72 hours - You have liver disease, a history of seizures, or severe cardiovascular disease - You are allergic to the study drugs - You are enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLong-acting Cabotegravir injection

Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.

OTHERSEARCH-YOUTH

It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.